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Objectives: Epstein-Barr virus has been recently associated with the onset of multiple scle-
rosis,  yet understanding how it elicits autoimmunity remains elusive. We  investigated the
relation between Epstein-Barr virus reactivation and disease development in different sub-
types of multiple sclerosis.
Methods:  In the present research, we have determined the Epstein-Barr virus-DNA load by
quantitative real-time polymerase chain reaction and Epstein-Barr virus antibody levels by
EIA technique in both multiple sclerosis patients (n = 78) and healthy controls (n = 123).
Results:  Our results demonstrated increased titer of both anti-Epstein-Barr virus-IgG and
IgM  antibodies in patients (91.02% vs 82.11% in controls, p < 0.001 and 14.1% vs 4.06% in
controls,  p < 0.001, respectively). Overall, Epstein-Barr virus reactivation was  found in 68.75%
of  subtypes of multiple sclerosis, 4.54% of multiple sclerosis primary subtype, and in only
3.25%  of healthy control subjects. Moreover, in samples of patients with disease relapse(exacerbation)  cell free viral DNA was elevated in contrast to other patients (p < 0.001).
Conclusions:  These ﬁndings provide further support for the detrimental effects of Epstein-
Barr  virus in the reactivation of multiple sclerosis attacks.
but  certain Human Herpes Viruses (HHVs) have been linked
with  the development of MS.4,5 There is strong epidemio-
© 2013 Elsevier Editora Ltda.  Este é um artigo Open Access sob a licença de CC BY-NC-NDIntroduction
Multiple sclerosis (MS) is the most prevalent demyelinating
disease among young adults, affecting many  people in the
developing  countries.1 There are several different forms of MS.
In some cases, symptoms are present all the time and get pro-
gressively  worse. In other cases, the symptoms tend to come
and  go in periods of remissions and exacerbations (ﬂares,
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1413-8670      © 2013 Elsevier Editora Ltda. 
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Este é um artigo Open Access sob a licençarelapses or attacks).2 An important step in managing this
condition is identifying the factors that cause MS  exacerba-
tions,  and then taking actions to minimize exposure.3 No virus
has  been deﬁnitively implicated as a causative factor for MS,8615-538, Mofateh Sq., Zabol, University, Zabol, Iran.
Sanadgol).
logic evidence linking MS to infection with the B-lymphotropic
-herpesvirus Epstein-Barr virus (EBV).6,7 However, the
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nderlying mechanisms currently remain elusive. One
ypothesis is that EBV or EBV-infected B cells might directly
nﬁltrate  the CNS, eliciting an EBV-speciﬁc immune response
hich  subsequently leads to damage of surrounding tissue.8,9
t is also proposed that deprivation of sunlight and vita-
in  D at higher latitudes facilitates the development of
S.10 Several hypotheses have been addressed to explain the
reaking  of immune tolerance by EBV, including molecular
imicry between viral and myelin components,11–13 EBV-
nduced expansion of auto-reactive B cells,14 and induction of
eat-shock  proteins and super-antigens,15 but evidence that
hese  mechanisms are relevant to MS  is not available yet.
ecause  of its ability to establish a latent infection in B cells,
o  promote their proliferation and activation, and to reactivate
eriodically providing a constant antigenic challenge to the
mmune  system, EBV is well suited to be a trigger of chronic
nﬂammatory states and exacerbation in MS.16,17 In this case-
ontrol  study we  attempted to determine the seroprevalence
f  anti-EBV antibodies (IgG and IgM) and distribution of EBV-
NA  in various specimens to determine the role of systemic
ctive  EBV infection in pathogenesis of MS.
aterials  and  methods
atients  and  samples
he study, approved by the Zahedan University of Medical Sci-
nce  Multiple Institutional Review Board, was  conducted with
ll  clinical samples from MS  patients who were  treated at the
epartment  of Neurology, Ali-ebn Abitaleb Hospital, Zahedan,
ran,  and also, Healthy Blood Donors (HBD) who voluntarily
greed to participate in this research at the central medical
aboratory of Zahedan from December 2008 through July 2010.
S  patients (in southeast of Iran) were  diagnosed with Mag-
etic  Resonance Imaging (MRI) and McDonald criteria were
ollected.18 We  analyzed 201 different samples; 78 patients
nd  123 people as the healthy control group. The patient group
omprised  22 men  (mean age, 28.8 years; age range, 17–48
ears)  and 56 women  (mean age, 30.3 years; age range, 16–52
ears).  The control group of HBD comprised 34 men  (mean
ge,  26.4 years; age range, 17–42 years) and 89 women (mean
ge,  26.0 years; age range, 17–50 years).19 EDSS score for all
atients  at the time of inclusion were  below scale 5.0, except
f  three individuals with secondary progressive MS  (SPMS)
scale  6.5] and ﬁve with relapsing remitting multiple sclero-
is  (RRMS) [scale 5.0]. All patients had at least one annual
elapse, during two years before inclusion in the study. Serum,
BMCs  and unstimulated whole saliva samples were collected
y  standard methods. A total of 38 CSF samples (1.5 mL)  were
ollected  from MS  patients (RRMS = 22, SPMS = 6, primary pro-
ressive  multiple sclerosis – PPMS = 10) after lumbar puncture
LP)  in sterile containers and were  centrifuged for 15 min  at
80  g at 20 oC to obtain cell-free supernatants. Serum sam-
les  from 11 patients with RRMS and six patients with SRMS
17  samples in total) were obtained during periods of disease
xacerbation and the relation was  tested between deﬁned EBV
eactivation  periods and exacerbation rate for a mean of one
ear.  All Specimens were  stored at −70 ◦C until the experiment
as  performed. Multiple specimens were available for each3;1 7(2):156–163  157
patient, and all of them were  tested. When possible, clinical
materials were  tested more  than once.
DNA  extraction  and  quantitative  real-time  PCR  (qPCR)
EBV DNA extraction was performed for 100 L of samples
using RIBO-prep nucleic acid extraction kit (Interlabservice,
Moscow, Russia) according to the manufacturer’s proto-
col.  Real-time PCR was  performed using the AmpliSens
EBV-screen-FRT kit (Inter lab service) according to the man-
ufacturer’s  protocol. This real-time PCR assay showed to be
sensitive,  speciﬁc, and reproducible. The assay has an internal
control,  which allows inefﬁcient extraction or PCR inhibition
to  be detected. Real-time ampliﬁcation was  carried out using
10  L DNA eluate combined with 10 L PCR-mix-1-FL and
5  L PCR-mix-2-FL using Rotor-Gene 3000 Instrument (Cor-
bett  Research, Sydney, Australia) with the following cycling
parameters: pre-denaturation at 95 ◦C for 15 min, 95 ◦C for 5 s,
60 ◦C for 20 s and 72 ◦C for 15 s for 45 cycles. Data acquisition
was performed in both JOE/HEX/Yellow channel for EBV DNA
and  in the FAM/Green channel for -Globin gene DNA dur-
ing  the annealing (60 ◦C) stage. For quantiﬁcation of EBV DNA
two  standard positive samples of KSG1 (104 copies per reac-
tion  mixture) and KSG2 (102 copies per reaction mixture) were
included  in the run (Interlabservice). Calculations of Ct, prepa-
ration  of standard curve and quantiﬁcation of DNA in each
sample  were performed by Rotor-Gene Operating Software,
version 1.8 (Corbett Research).
EBV  antibody  response
Concentrations of serum EBV IgG VCA and IgM VCA were
measured based on EIA method in an automated instrument,
according to the manufacturer’s instructions (Biotrin, The
Rise,  Mount Merrion, Co., Dublin, Ireland).
Viral  reactivation  markers
In this study, we considered reactive EBV infection, when IgG
and  IgM were positive by immunoassay, and/or two or more
consecutive positive qPCR, and/or load EBV ≥ 200 copies in
serum,  or ≥150 copies in both saliva and PBMNCs.
Statistical  considerations
The Statistical Package for Social Sciences (SPSS Inc., Chicago,
IL,  USA), Version 16 was  used for statistical analysis. 2
analysis was applied to analyze categorical variables, t tests
for  continuous variables and Mann–Whitney U tests for
non-parametric variables. The nominal variable groups were
compared  by Pearson’s correlation coefﬁcient. All p-values are
two-tailed and signiﬁcant at p < 0.05 or p < 0.01 depending on
the  statistical method. Relative risk was calculated using the
Word  Processing, Database, and Statistic Program for Public
Health  Epi Info 6, Version 6.04B [Centers for Disease Con-
trol  and Prevention (CDC), USA, World Health Organization,
Geneva, Switzerland].
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Table 1 – Prevalence of EBV-DNA (copies/mL) and EBV-antibodies (U/mL) among controls and MS  patients. EBV-DNA was
analyzed via qPCR as described previously. Concentration of plasma anti-EBV, IgG and IgM were measurement in an
automated instrument, according to the manufacturer’s instructions. Data are representative of three independent
experiments.
Patients (n = 78) Controls  (n = 123) Sig.  (2-tailed)
P/N (%) [mean ± SD]
Anti-IgG (U/mL) 71/7(91.02) [20.26 ± 6.67] 101/22(82.11) [15.06 ± 4.22] P = 0.001
Anti-IgM (U/mL) 11/67(14.10) [31.24 ± 3.73] 5/118(4.06) [24.70 ± 2.14] P = 0.001
Saliva-DNA (copies/mL) 39/39(50) [134 ± 18.75] 47/76(38.21) [158 ± 41.18] P = 0.001
Serum-DNA (copies/mL) 30/48(38.46) [289 ± 62.16] 21/102(17.07) [274 ± 41.87] NS
PBMCs-DNA (copies/mL) 53/25(67.94) [160 ± 52.04] 51/72(41.46) [155 ± 29.91] NS
 P, poPBMCs, peripheral blood mononuclear cells; CSF, cerebrospinal ﬂuid;
Ethical  considerations
The study conformed to the Helsinki declaration and was
reviewed  and approved by the local research committee; writ-
ten  informed consent was  obtained from all subjects.
Results
Detection  of  IgG  and  IgM  antibodies  against  EBV-VCA
Recent studies have demonstrated that at least 91.02% of MS
patients  are positive for EBV- speciﬁc IgG (IgG+) antibodies
in  contrast with 82.11% of healthy controls (Table 1). 100% of
SPMS  patients were  IgG+ in their serum samples compared to
93.47% of the RRMS, and 80.95% of PPMS samples (Table 2). The
detection  of anti-EBV IgM from healthy volunteer donors and
MS  patients, independent of EBV-DNA detection in PBMCs, is
indicative only of a new infection and found in 3.25% of con-
trols  but in none of the patients (p < 0.05). Moreover, among
MS  subtypes, only SPMS (36.36%) and RRMS (15.21%) patients
showed  anti-EBV-IgM as a sign of reactivation in their serum
in  contrast with PPMS (p < 0.001). On the other hand, patients
Table 2 – Prevalence of EBV-DNA (copies/mL) and EBV-antibodie
analyzed by qPCR as described previously. Concentration of pla
automated instrument, according to the manufacturer’s instruc
experiments.
Saliva Serum PBMCs
MS (n = 78)
1RRMS (n = 46) 28/18 (60.86) 21/25 (45.65) 37/9 (80.4
CSF (n = 22) [131 ± 14.27] [288 ± 46.90] [160 ± 53.
2SPMS (n = 11) 9/2 (81.81) 8/3 (72.72) 10/1 (90.9
CSF (n = 6) [144 ± 28.40] [307 ± 85.17] [185 ± 51.
3PPMS (n = 21) 2/19  (9.52) 1/20 (4.76) 6/15 (28.5
CSF (n = 10) [128 ± 7.07] [168] [122 ± 7.5
Sig. (2-tailed)
Subtypes(1,2) NK NS NS 
Subtypes(1,3) NS P < 0.05 P < 0.01 
Subtypes(2,3) NS P < 0.001 P < 0.05 
PRMCs, peripheral mononuclear cells; CSF, cerebrospinal ﬂuid; PPMS, prim
progressive MS; P, positive; N, negative; NS, not signiﬁcant.sitive; N, negative; NS, not signiﬁcant.
had higher concentration of both IgM and IgG compared to
controls  (Table 1).
Load  of  viral  genome  in  clinical  samples
EBV DNA load in serum samples did not differed between MS
patients  and controls (Table 1). In the saliva samples, 50%
of  patients were EBV+ compared to 38.21% of the controls
(Table 1). Viral DNA was  found in all saliva samples that pre-
viously  were positive for viral DNA in their PBMCs both in
patients  and controls. Saliva showed much  higher prevalence
of  viral sequence than serum samples in controls (p = 0.001). In
the PBMCs samples, 67.94% of patients were EBV+ in contrast
to  41.46% of the controls (Table 1). EBV DNA was  detected only
in  seven CSF samples of RRMS (31.81%) and four CSF sam-
ples  of SPMS (66.66%) obtained during an exacerbation but
were  not found in CSF of patients with remission or patients
with  PPMS (Table 2). As shown in Table 2, 80.43% of patients
with  RRMS, 90.9% of patients with SRMS and 28.57% patients
with  PPMS had EBV sequences (EBV+) in PBMCs. Six patients
with  RRMS (13.046%) and four patients with SRMS (36.36%)
showed further positivity in all specimens (Table 2). Further-
more,  among patients’ samples, 11 (14.1%) individuals showed
s (U/mL) among different subtypes of MS.  EBV-DNA was
sma anti-EBV, IgG and IgM were  measurement in an
tions. Data are representative of three independent
 CSF Anti-IgG Anti-IgM
P/N (%) [mean ± SD]
3) 7/15 (31.81) 43/3 (93.47) 7/39 (15.21)
29] [141 ± 20.81] [21.37 ± 6.51] [31.68 ± 4.09]
0) 4/2 (66.66) 11/0 (100) 4/7 (36.36)
25] [131 ± 10.00] [24.60 ± 6.38] [30.47 ± 3.41]
7) 0/10 (–) 17/4 (80.95) 0/21 (–)
0] [–] [14.62 ± 2.82] [–]
NS NS NS
– P < 0.001 –
– P < 0.001 –
ary progressive MS; RRMS, relapsing-remitting MS; SPMS, secondary
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1Fig. 1 – Prevalence of EBV-DNA and anti-EBV antibodies a
ositive results in all specimens in contrast to none of the
ontrols  (Table 2).
ystemic  infection  and  disease  exacerbation
ystemic EBV infections were found in 68.75% of patients
nd  in only 4.54% of controls (p < 0.001). As a measure of
eactivation, combined qPCR results and IgG serology showed
hat  16.66% of the patients had reactive EBV infections com-
ared  to 3.25% of controls. Reactive viral infection in these
atients  was  conﬁrmed by the detection of speciﬁc anti-EBV
gM  antibodies in their serum. Viral DNA in serum and spe-
iﬁc  IgM antibodies in plasma were not detected in 82.11%
f  healthy controls (101/123) and 48.71% of patients (38/78). A
trong association was  found between EBV reactivation and
S  attacks when MS  primary stages (4.54%) were compared
o  other stages (p < 0.001). Neither viral DNA in serum, nor
he  presence of IgM speciﬁc antibodies, or elevated titers of
gG  antibodies to EBV were  found in 8.69% of RRMS (4/46),
8.18%  of SPMM (2/11) and 42.85% of PPMS (9/21), conﬁrming
hat  in these patients EBV infection remained latent. Episodes
f  deﬁned EBV reactivation were observed in a subgroup
11  patients with RRMS and six patients with SRMS), and
hese  episodes were  associated with increased relative risk
RR)  for disease exacerbation. In these subgroup of patients,
he  annual number of reactivation was  3.1 in the group of
1  patients who had one or more  relapses, compared to
.12  in the group of six patients who did not experience ag male and female in healthy controls and MS  patients.
relapse (p < 0.05). In a 4-week period beginning two weeks
before  reactivation and ending two weeks after reactivation,
the  RR of relapse was  3.5 (p < 0.05) compared to all other
periods. Furthermore, all patients with disease exacerba-
tion  showed reactivated infection and EBV-DNA in their CSF
samples.  Prevalence of EBV-DNA and anti-EBV antibodies
was  demonstrated by a comprehensive analysis performed
among  males and females in both control and patient groups
(Figs.  1 and 2). In all cases, female patients showed higher
positivity (Fig. 1) and systemic EBV infection was  more  preva-
lent  among females compared to males (p < 0.001). Female
patients with SPMS showed higher prevalence of EBV-DNA and
anti-EBV  antibodies compared to both males and other MS
subtypes  (Fig. 2). Increased EBV-DNA concentrations tended
to  be associated with EBV systemic infection, but associations
with  additional components such as MS subtypes and gender
were  even stronger.
Correlations  between  seroanalysis  and  DNA  detection
Signiﬁcant difference and positive correlation with concen-
tration  of EBV-DNA in saliva and EBV-DNA in serum were
found  in both groups (p < 0.005), but a signiﬁcant inverse
correlation with EBV-IgG and IgM response was found only
in  the patient group (Tables 3 and 4). No correlation was
found  between detection of EBV-DNA in CSF and detection
of  EBV-DNA in other samples, or with EBV-IgG and IgM con-
centrations  (Table 3). Serologically, immune status showed
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Fig. 2 – Prevalence of EBV-DNA and anti-EBV antibodies among male and female in different subtypes of MS.
Table 3 – Correlation of EBV-DNA detection in different specimens (EBV+) with EBV seroprevalence in MS  patients.
Correlations in MS patients
IgG IgM Serum PBMCs Saliva CSF
EBV-IgG (U/mL)
Pearson  correlation 1 −.412 .437* .580** .308 .244
Sig. (2-tailed) .209 .016 .000 .057 .469
EBV-IgM (U/mL)
Pearson  correlation −.412  1 −.242 −.286 −.217 −.308
Sig. (2-tailed) .209 .474 .393 .521 .387
Serum DNA (copies/mL)
Pearson  correlation .437* −.242 1 .211 .436* .121
Sig. (2-tailed) .016 .474 .264 .026 .723
PBMCs DNA (copies/mL)
Pearson  correlation .580** −.286 .211 1 .146 .314
Sig. (2-tailed) .000 .393 .264 .380 .346
Saliva DNA (copies/mL)
Pearson  correlation .308 −.217 .436* .146 1 −.248
Sig. (2-tailed) .057 .521 .026 .380 .463
CSF DNA (copies/mL)
Pearson correlation .244 −.308 .121 .314 −.248 1
Sig. (2-tailed) .469 .387 .723 .346 .463
∗ Correlation is signiﬁcant at the 0.05 level (2-tailed).
∗∗ Correlation is signiﬁcant at the 0.01 level (2-tailed).
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Table 4 – Correlation of EBV-DNA detection in separate specimens (EBV+) with EBV seroprevalence in healthy controls.
Correlations in healthy controls
IgG IgM Serum PBMCs Saliva
EBV-IgG (U/mL)
Pearson  correlation 1 .457 .300 .570** .562**
Sig. (2-tailed) .543 .199 .000 .000
EBV-IgM (U/mL)
Pearson  correlation .457 1 −.083 −.940 −.343
Sig. (2-tailed) .543 .917 .060 .572
Serum DNA (copies/mL)
Pearson  correlation .300 −.083 1 .216 .549**
Sig. (2-tailed) .199 .917 .346 .012
PBMCs DNA (copies/mL)
Pearson  correlation .570** −.940 .216 1 .617**
Sig. (2-tailed) .000 .060 .346 .000
Saliva DNA (copies/mL)
Pearson  correlation .562** −.343 .549* .617** 1
Sig. (2-tailed) .000 .572 .012 .000
p
E
n
E
(
I
b
o
c
i
f
I
D
A
1
h
g
e
b
a
m
o
m
m
a
t
g
n
M
i
s
r
s
a∗ Correlation is signiﬁcant at the 0.05 level (2-tailed).
∗∗ Correlation is signiﬁcant at the 0.01 level (2-tailed).
oor correlation with IgG concentration and detection of
BV-DNA  in serum for both groups (p < 0.005). There were
o  statistically signiﬁcant correlations between detection of
BV-DNA  in serum and EBV-DNA in PBMCs in both groups
Tables  3 and 4). There was  direct correlation between EBV-
gG  concentration and detection of EBV-DNA in PBMCs in
oth  groups (Tables 3 and 4). Again, a positive correlation was
bserved  between EBV-DNA in saliva and increased EBV-IgG
oncentration only among patients (Table 3). We  found a pos-
tive  correlation between the detectability of EBV-DNA in CFS
rom patients and exacerbation, as well as a decrease in EBV
gG/IgM  ratio.
iscussion
 viral trigger involved in MS  has been suggested more  than
00  years ago,20 and an extensive list of candidate viruses
as  emerged since then. Several clinical studies have sug-
ested  that MS  in general as well as episodes of disease
xacerbation are associated with concomitant viral or micro-
ial  infections.21–23 Virus may  play a role, since MS relapses
re  often associated with common viral infections.24 Although
any  infectious microorganisms have been investigated, no
rganism has emerged as a proven trigger. Different patients
ay  be affected by different organisms, and the infections
ay  cause some, but not all, cases of MS.  Organisms that
re  at the top of the suspect list are those that can affect
he  central nervous system. The role of EBV in the patho-
enesis of MS  has been debated in recent years and it has
ot  been clariﬁed whether active EBV infection is speciﬁc to
S.25–28 The frequency of EBV speciﬁc IgG (measuring latent
nfection) in normal population was  82.92%, relatively con-
istent  with the average global frequency of 90%.29 However,
esearchers have discovered that people who are especially
ensitive to the virus and have unusually high levels of EBV
ntibodies  may  have a greater risk of developing MS.30,31 Inrecent years, there has been an improved understanding of the
epidemiology,  pathogenesis, and long-term disabilities asso-
ciated  with EBV infection.32–34 There are evidences that EBV
reactivation is associated with clinical disease activity in MS
when  reactivation is deﬁned as a pattern of increased IgM and
IgA  levels against EBV.35 Although viral load does not appear to
differ between MS  patients and healthy EBV-infected controls,
the  presence of EBV-DNA has been detected more  frequently in
serial samples of MS patients with high disease activity com-
pared  to those with low disease activity.36–38 The major focus
of  our research was  to characterize the extent and distribu-
tion  of EBV in the pathogenesis of MS.  Very little is known
about  the prevalence of EBV in Iranian MS patients or general
population. Analysis of serum EBV-DNA demonstrated that
there  is a statistically greater likelihood of detecting EBV-DNA
in  the CSF of SPMS patients than other courses. This study
supports the role of EBV in the pathogenesis of MS by sug-
gesting  that the presence of systemic EBV infection coincides
with  developing courses (SPMS and RRMS). We  suggest that
there  may  be multiple ‘triggers’ by which foreign antigens,
including infectious agents, may  be associated with immune
attacks  on the CNS. We also propose that EBV may  be one
such  trigger and if so, the mechanism(s) by which this virus
is  associated with the pathogenesis of MS  will be important
to  deﬁne. Salivary glands are a potential site for EBV persis-
tence  and saliva is a vehicle for transmission of the virus,
either  from mother to child or between children. EBV-DNA
detection in PBMC and salivary glands has no clinical rele-
vance  because the virus can be latent in them and its presence
does  not discriminate between active infection and latent
stages.  SPMS patients had signiﬁcantly higher levels of serum
EBV  IgM compared to other patients. Increased IgM antibod-
ies  beside systemic infection could represent EBV reactivation
and  would be consistent with the hypothesis that this virus
may  be linked with MS pathogenesis. These results agree with
the  ﬁnding of researchers who reported a higher positivity
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for EBV-DNA and antibodies in serum and CSF of MS patients
with  exacerbation.39–45 We  emphasize that only through well-
controlled  intervention clinical trials with effective and safe
antiviral  can a causal role be of any infectious agent in MS
could  be tested. In conclusion, high levels of EBV-DNA have
been  detected in serum, saliva and CSF of MS patients with
exacerbation, as well as in their PBMCs. Due to the high
prevalence of latently infected individuals in the healthy pop-
ulation, it was  difﬁcult to establish a causative role of EBV in
this  disease. The majority of healthy subjects are seroposi-
tive  for the virus, and studies showed high reactivation of EBV
in  patients with RRMS and SPMS. Recently, it was  shown that
56.41%  of PBMCs from MS  patients harbor EBV-DNA in a latent,
nonproductive form, which dramatically differ from the con-
trol  population (35.77%). Therefore, to establish a correlation,
it  is necessary to discriminate between latent and productive
infections. The association of EBV with MS  remains controver-
sial  and a more  extensive understanding of EBV neurotropism
and  its association with the disease process is required.
Conclusions
The reactivation of EBV infection in MS  patients was supported
by  serologic ﬁndings and molecular detection. As prevalence
of  anti-EBV IgG in serum and EBV-DNA in PBMCs in both
patient  and control groups was  relatively similar, we con-
cluded  that both patients and controls had active infection
previously and recently established latent infection. Alterna-
tively,  because of high copy number of DNA in serum and
also  lower titer of anti-EBV IgG in contrast with anti-EBV IgM
observed  in patients with RRMS and SPMS, we  propose that
reactivation occurred in this group. On the other hand, the
presence  of EBV-DNA in CSF samples, which is a sharp marker
of  reactive viral infection, was  detected only in patients with
progressive  MS  and strongly validated our hypothesis. The
absence  of EBV-DNA in CSF of some patients with active MS
may  be associated with an early stage of viral replication.
Although this study is prospective in design, we cannot deﬁni-
tively  prove that EBV plays a causative role in MS.
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